This study estimated the prevalence of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) serological markers among inmates and evaluated inmates'compliance with an HBV immunization programme.
During the mandatory consultation at the sexually transmitted disease (STD) clinic of the Marseille Prison (HIV counselling, and syphilis/HIV screening), physicians offered serological testing (anti-HBs, anti-HBc, HbsAg, anti-HIV) and Engerix B vaccination to each entrant.
The number participating in the survey is 391/411 (89%) ; 75% were aged 18 to 35 years and 79% were men ; 42% reported having had multiple sexual partners during the last 12 months.
Report of an intravenous drug user (IDU) sexual partner was more frequent among women than men (22% vs 8%). Injecting drug use over lifetime was reported by 23% ; 27% declared having shared their injection equipment during the last 12 months. 124/267 (32%) had an HBV marker :
Report of an intravenous drug user (IDU) sexual partner was more frequent among women than men (22% vs 8%). Injecting drug use over lifetime was reported by 23% ;
anti-HBs+only (immunized) : 2.3% ;
anti-HBs+and anti-HBc+21.7% ;
anti-HBc+only : 6.4% ;
HBsAg+1.3%. The HIV seroprevalence was 6% (21% among IDUs).
This survey underlines the high HBV and HIV seroprevalence among prisoners and the high proportion of inmates at risk for these infections.
There is an urgent need for immunization and education programmes in this population.
It demonstrates an HBV immunization programme is feasible and accepted by inmates and staff members.
Mots-clés Pascal : SIDA, Virose, Infection, Milieu carcéral, Dépistage, Hépatite virale B, Programme sanitaire, Vaccination, Immunoprophylaxie, Homme, Sérologie, France, Europe, Facteur risque, Immunopathologie, Immunodéficit, Prévention, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Carceral environment, Medical screening, Viral hepatitis B, Sanitary program, Vaccination, Immunoprophylaxis, Human, Serology, France, Europe, Risk factor, Immunopathology, Immune deficiency, Prevention, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0046214
Code Inist : 002B05C02D. Création : 14/05/1998.